This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
André, F. et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet https://doi.org/10.1016/S0140-6736(23)00725-0 (2023)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. T-DXd is effective after T-DM1. Nat Rev Clin Oncol 20, 426 (2023). https://doi.org/10.1038/s41571-023-00779-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-023-00779-6
This article is cited by
-
From pre-clinical to translational brain metastasis research: current challenges and emerging opportunities
Clinical & Experimental Metastasis (2024)